spacer
home > ebr > summer 2019 > closer to the cure
PUBLICATIONS
European Biopharmaceutical Review

Closer to the Cure

Cancer has always been with us. For most of history, it was entirely untreatable; now, two out of three Americans with invasive cancer survive for at least five years. Overall cancer survival rates in the UK have doubled over the past 40 years; now, most people diagnosed with cancer live for at least 10 more years. Though a lot of progress has been made, it is uneven, and the next set of breakthroughs will require accepting a high risk of failure. We will need to look beyond incremental change towards potential cures.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christian Rommel is Roche’s Global Head of Pharma Research and Early Development (pRED) Oncology. Before that, he led the pRED Oncology Discovery group from 2014 to 2018. Previous to joining Roche, he held the positions of Vice President of External Research and Development and Vice President of Research Oncology at Amgen. Christian served as Chief Scientific Officer at a private biotechnology company (Intellikine) from its inception to acquisition by Takeda in 2011. Previously, Christian was Head of Target Research at Merck Serono from 2000 to 2007. Over the course of his career, Christian authored more than 70 publications and was an inventor or co-inventor of 18 patents. Christian received his PhD in molecular oncology/signal transduction from the Max Planck Institute in Berlin, Germany, and the Institute of Medical Virology at the University of Zurich, Switzerland.
spacer
Christian Rommel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge CPhI & P-MEC China a direct result of surging manufacturing

Shanghai, 22 July, 2019:CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market in China continues to grow. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement